EGFR T790M/L858R-IN-9_product_DataBase

Bioactivity	EGFR T790M/L858R-IN-9 (Compound 8) is an EGFR-L858R/T790M inhibitor that demonstrates potent inhibitory phosphorylation effects against the EGFR-L858R/T790M mutant kinase, with an IC50 value of 0.0064µM. EGFR T790M/L858R-IN-9 also inhibits the proliferation of non-small cell lung cancer (NSCLC) cells and can be utilized in cancer research[1].
Target	IC50: 0.0064 μM (EGFRT-790M/L858R).
Invitro	EGFR T790M/L858R-IN-9 (Compound 8) 在突变型和野生型 NSCLC 细胞系中具有抗增殖活性，其 IC50 值分别为 0.170 μM (携带EGFR-L858R/T790M突变的H1975细胞增殖) 和 0.554 μM (A549 细胞)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> EGFR T790M/L858R-IN-9 相关抗体:
Formula	C26H27N7O3S
Molar Mass	517.60
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Ahmad I, et al. Design, Synthesis, and Evaluation of Novel 2, 4‐disubstituted Pyrimidine Derivatives as Double Mutant Epidermal Growth Factor Receptor‐L858R/T790M Tyrosine Kinase Inhibitors[J]. Journal of Biochemical and Molecular Toxicology, 2025, 39(1): e70077.

PeptideDB